Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy

BACKGROUND-: Data exist that demonstrate isoflavones' potent antiproliferative effects on prostate cancer cells. We evaluated the efficacy of isoflavone in patients with PSA recurrent prostate cancer after prior therapy. We postulated that isoflavone therapy would slow the rate of rise of serum...

Descripción completa

Detalles Bibliográficos
Autores principales: Pendleton, John M, Tan, Winston W, Anai, Satoshi, Chang, Myron, Hou, Wei, Shiverick, Kathleen T, Rosser, Charles J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394534/
https://www.ncbi.nlm.nih.gov/pubmed/18471323
http://dx.doi.org/10.1186/1471-2407-8-132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394534/
https://www.ncbi.nlm.nih.gov/pubmed/18471323
http://dx.doi.org/10.1186/1471-2407-8-132

Ejemplares similares